Oric Pharmaceuticals (ORIC) investor relations material

Program overviews and strategic focus

• Two late-stage programs target prostate and lung cancer, both with differentiated profiles and strong development progress.

• Rinzimetastat is in a phase III trial (Himalayas-1) for castration-resistant prostate cancer, with enozertinib expected to enter phase III next year for lung cancer.

• Both programs are well-funded, with a cash runway into the second half of 2028, covering key trials.

• Expansion plans include additional phase III studies in prostate cancer and potential new indications.

• Preclinical work explores combinations with other targets in prostate and other cancers.

Competitive landscape and clinical expectations

• Pfizer's MEVPRO-1 phase III readout in Q4 is expected to impact perceptions and modeling for similar therapies.

• Clinically meaningful results in prostate cancer would be PFS improvements beyond four to six months, with double-digit PFS considered game-changing.

• Safety differentiation is a key advantage for rinzimetastat, attributed to its longer half-life and lack of CYP induction compared to competitors.

• EED inhibition may offer resistance advantages over EZH2 inhibitors, though this remains preclinical for now.

• Low risk of secondary malignancy is not seen as a barrier in oncology, with ongoing FDA engagement and no concerning signals in current studies.

Development timelines and upcoming catalysts

• Himalayas-1 phase III trial for rinzimetastat is ongoing, with top-line data expected in the first half of 2028.

• Second-half program updates may include study progress, new phase III plans, or additional data.

• Enozertinib is being developed for EGFR exon 20 and atypical mutations in lung cancer, with a focus on CNS activity and safety.

• Data updates for both programs are expected in the next 12–18 months, alongside key competitor readouts.

• The company is positioned to efficiently execute trials and respond to evolving data in both prostate and lung cancer spaces.